Singla, N., Minkowitz, H.S., Soergel, D.G., Burt, D.A., Subach, R.A., Salamea, M.Y., et al. (2017) A Randomized, Phase IIb Study Investigating Oliceridine (TRV130), a Novel Micro-Receptor G-Protein Pathway Selective (μ-GPS) Modulator, for the Management of Moderate to Severe Acute Pain Following Abdominoplasty. Journal of Pain Research, 10, 2413-2424.

has been cited by the following article:

• TITLE: “New-Look” Opioids: Biased Ligands

  AUTHORS: Joseph V. Pergolizzi, Michael H. Ossipov, Robert Taylor, Robert B. Raffa

  KEYWORDS: Pain, Analgesic Drugs, Opioids, G Protein-Coupled Receptors, Biased Ligands

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.9 No.7, July 18, 2018

  ABSTRACT: Between the illicit use of opioids and attendant overdoses, and accidental overdoses with prescribed drugs, overuse of opioids has become a serious problem. At the same time, finding that fine balance between minimizing the risk of opioid misuse and abuse while at the same time providing access to treatment for patients who need pain control presents an ongoing challenge. Efforts to discover and develop better agents have led to what we term “new-look” opioids. We summarize here one such approach—known as biased ligands. By targeting a subset of GPCR signal transduction, this approach attempts to increase the separation between therapeutic and adverse effects.